Year: 2021

Ad hoc announcement pursuant to Art. 53 LR Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY studyIdorsia will consult with health authorities and share the data collected so far to define the regulatory pathway for lucerastat in Fabry diseaseAllschwil, Switzerland – December 13, 2021Idorsia Ltd (SIX: IDIA) today announced that after the planned interim analysis of the open-label extension (OLE) of the Phase 3 MODIFY study with lucerastat for the treatment of adult patients with Fabry disease, the study will continue. The company will consult with health authorities in the first half of 2022, and discuss the data collected up until the first interim analysis of the OLE study. The data includes the placebo-controlled 6-month treatment period with...

Hydro continues to strengthen the company in terms of profitability and sustainability and is announcing new improvement targets as well as new sustainability ambitions. Along with an update on the strategic direction toward 2025 on low-carbon aluminium and new energy, these will be key topics at Hydro’s Capital Markets Day 2021. During 2021, Hydro has continued to deliver on its 2025 strategy, including further strengthening its low-carbon aluminium position as well as maturing business opportunities within new energy solutions. Hydro has long been recognized as a leader in sustainability, and the new sustainability ambitions launched at the Capital Markets Day will be a key driver for Hydro’s competitive positioning going forward. Hydro has the ambition of achieving net zero carbon emissions by 2050 or earlier and is pursuing three decarbonization...

Mullen is following up on success from the L.A. Auto Show by attending the CES® in Las Vegas, Jan. 4 – 8. Mullen will showcase the Mullen FIVE EV Crossover and introduce level 5 autonomous, powertrain and battery technologyMullen to Showcase FIVE EV Crossover and Debut New Level 5 Autonomous Technology at CES® in Las Vegas, January 2022Mullen Automotive will be at the 2022 CES® (Consumer Electronic Show), Jan. 4 – 8, 2022.BREA, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces that its next stop in showcasing the Mullen FIVE EV Crossover, including the debut of level 5 autonomous vehicle technology, will be at CES® in Las Vegas, Jan. 4 – 8, 2022. Mullen will showcase...

NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $2.0 million, before deducting underwriting discounts and commissions and other estimated expenses payable by the Company. The offering equates to 1,910,100 shares at a price to the public of $1.07 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. In addition, the Company granted the underwriters a 45-day option to purchase additional shares of common stock, representing up to 15.0% of the number of the shares, solely to cover over-allotments, if...

Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a potential therapeutic approach for solid tumors iNKs with double knock-in of CD16 and mbIL-15 in combination with monoclonal antibodysignificantly reduce tumor burden iNKs with double knock-out of CISH and TGFβR2 substantially reduce tumor burden CAMBRIDGE, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported in vitro and in vivo preclinical data on the enhanced tumor killing capacity of two modified induced pluripotent stem cell (iPSC)-derived natural killer (or iNK) cell therapies using Editas Medicine’s proprietary AsCas12a gene editing. The Company reported these findings in a presentation today at the 63rd...

PURCHASE, NY, Dec. 12, 2021 (GLOBE NEWSWIRE) — Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, is providing free, 24/7 general medical telehealth visits to residents, first responders and others directly impacted by the devastating tornadoes in Kentucky. Individuals who are now being displaced can seek treatment from a licensed health care professional for any non-emergency illness by calling Teladoc directly at 855-225-5032. Among those adult and pediatric conditions that can be effectively diagnosed and treated as part of Teladoc’s general medical no-cost offering are common conditions including sinus problems, respiratory infections, allergies, cold and flu symptoms, and many other non-emergency illnesses. Individuals seeking physician-authorization for prescription refills of non-narcotic drugs...

Laboratory studies using full Omicron pseudovirus confirm ensovibep maintains ability to neutralize the variant with very high potency, relative to substantial reductions in neutralizing potency across numerous anti-SARS-CoV-2 antibody drugs Ensovibep continues to retain potent neutralization against all prior SARS-CoV-2 viral variants of concern, with an IC50 in the single digit ng/ml range Ensovibep is currently being evaluated in a global Phase 2-3 study (EMPATHY) in collaboration with NovartisZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that preclinical studies confirm...

Initial Phase 1/2 data presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition Phase 1/2 study of NEXI-002 as a monotherapy in patients with relapsed/refractory multiple myeloma patients who have failed ≥3 prior lines of therapy is ongoingGAITHERSBURG, Md., Dec. 12, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced preliminary Phase 1/2 results from an ongoing study of NEXI-002, a patient-derived multi-antigen-specific CD8+ T cell treatment for patients with relapsed/refractory multiple myeloma who have failed ≥3 prior lines of therapy. The data on low doses of NEXI-002, presented at...

For media: we have b-roll, pictures and additional information on our emergency response equipment available at our Emergency Resource Center – https://www.verizon.com/about/news/emergency-resource-center What you need to know:Verizon consumer (prepaid and postpaid) and small business* customers in parts of Kentucky and Illinois will receive unlimited calling, texting and data 12/12 through 12/18 Our Verizon Response team is available 24/7 to coordinate with first respondersBASKING RIDGE, N.J., Dec. 12, 2021 (GLOBE NEWSWIRE) — For our consumer and small business customers impacted by tornadoes in parts of Kentucky and Illinois, beginning Sunday, December 12 through December 18, Verizon is providing unlimited calling, texting and data to those who reside in the following: Kentucky: Mayfield, Owensboro Illinois: The hardest...